{
  "_metadata": {
    "version": "2.0",
    "ticker": "ARGX",
    "asset_name": "empasiprubart"
  },
  "asset": {
    "name": "empasiprubart",
    "ticker": "ARGX",
    "internal_id": "ARGX-117",
    "modality": "C2 sweeping antibody",
    "stage": "Phase 3",
    "one_liner": "First-in-class C2 complement sweeping antibody targeting MMN and CIDP with potential for combination with VYVGART",
    "ownership": "Wholly-owned"
  },
  "target": {
    "name": "C2 (Complement Component 2)",
    "full_name": "Complement Component 2",
    "class": "Complement pathway component",
    "pathway": "Classical/lectin pathway → C2 cleavage → C3 convertase formation → complement activation",
    "biology": {
      "simple_explanation": "C2 is a key component of the classical and lectin complement pathways. Empasiprubart uses a 'sweeping' mechanism to bind C2 and accelerate its clearance, providing sustained inhibition of complement activation upstream of C5 inhibitors.",
      "mechanism_differentiation": "Upstream C2 inhibition vs downstream C5 blockade (eculizumab, ravulizumab)",
      "sweeping_mechanism": "Antibody binds C2 and accelerates degradation for sustained complement suppression"
    },
    "why_good_target": {
      "clinical_validation": "Complement activation implicated in MMN, CIDP, and other neurological diseases",
      "unmet_need": [
        "MMN has zero approved targeted treatments",
        "60% of MMN patients progress despite IVIg treatment",
        "40% of MMN patients initially misdiagnosed (often as ALS)",
        "C2 deficiency is generally well-tolerated in humans"
      ]
    }
  },
  "indications": {
    "lead": {
      "name": "Multifocal Motor Neuropathy (MMN)",
      "stage": "Phase 3 EMPASSION",
      "rationale": "Zero approved targeted treatments; 60% progress on IVIg; >$1B market by 2030"
    },
    "expansion": [
      {
        "name": "CIDP",
        "stage": "Phase 2/3",
        "readout": "2H 2027",
        "rationale": "Second MOA after VYVGART; potential combination or sequential use"
      },
      {
        "name": "MG Combination",
        "stage": "ADAPT Forward study",
        "rationale": "Efgartigimod + empasiprubart combination for enhanced efficacy"
      }
    ]
  },
  "clinical_data": {
    "trial_name": "EMPASSION (Phase 3 MMN)",
    "trial_design": {
      "phase": "Phase 3",
      "design": "Head-to-head trial vs IVIg",
      "population": "MMN patients"
    },
    "phase_2_results": {
      "trial": "ARDA Phase 2 + ARDA+ Open Label Extension",
      "endpoint": "Grip strength change from baseline",
      "key_finding": "Sustained improved grip strength through 64+ weeks",
      "durability": "Improvements maintained in open-label extension",
      "cohorts": "EMP-EMP Cohort 1, EMP-EMP Cohort 2, PBO-EMP Cohort 1, PBO-EMP Cohort 2"
    },
    "safety": {
      "profile": "Generally well-tolerated in Phase 2",
      "note": "Phase 3 safety data pending"
    }
  },
  "catalysts": [
    {
      "event": "MMN Phase 3 EMPASSION readout",
      "timing": "4Q 2026",
      "importance": "critical",
      "what_to_watch": "Head-to-head vs IVIg; first Phase 3 for empasiprubart"
    },
    {
      "event": "CIDP Phase 2/3 readout",
      "timing": "2H 2027",
      "importance": "high",
      "what_to_watch": "Second molecule in CIDP; combination potential with VYVGART"
    }
  ],
  "competitive_landscape": {
    "complement_inhibitors": [
      {
        "drug": "eculizumab (Soliris)",
        "company": "Alexion/AstraZeneca",
        "target": "C5",
        "limitation": "Downstream inhibition; different mechanism"
      },
      {
        "drug": "ravulizumab (Ultomiris)",
        "company": "Alexion/AstraZeneca",
        "target": "C5",
        "limitation": "Long-acting C5 but still downstream"
      }
    ],
    "empasiprubart_advantages": [
      "First-in-class C2 sweeping mechanism",
      "Upstream complement inhibition",
      "Sustained C2 depletion through sweeping",
      "Combination potential with FcRn inhibition"
    ]
  },
  "investment_analysis": {
    "probability_of_success": "Phase 2 de-risked; Phase 3 head-to-head vs IVIg",
    "peak_sales_estimate": ">$1B in MMN alone; additional upside from CIDP",
    "key_risks": [
      "Novel mechanism without approved precedent",
      "Head-to-head trial vs IVIg is challenging design",
      "Compound mutation market may be smaller than total addressable"
    ]
  },
  "market_opportunity": {
    "mmn_global": "12,000 patients across key markets",
    "mmn_market_today": "$750-800M",
    "mmn_market_2030": ">$1B",
    "mmn_unmet_need": "40% misdiagnosed, 0 targeted treatments, 60% progress on IVIg, 20% severe disability",
    "cidp_opportunity": "42K diagnosed US patients; second MOA after VYVGART"
  }
}
